Reviva Pharmaceuticals Holdings, Inc. RVPH

RVPH Company Overview

Reviva Pharmaceuticals Holdings, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory, and cardiometabolic disorders. The company’s primary emphasis is the development of novel small-molecule drug candidates targeting unmet medical needs in psychiatry and neurology, particularly schizophrenia and related neuropsychiatric conditions. Reviva operates within the biotechnology and pharmaceutical industries and derives its value primarily from clinical development programs, intellectual property assets, licensing potential, and future commercialization opportunities rather than current product sales.

The company’s lead product candidate is brilaroxazine (RP5063), a serotonin-dopamine signaling modulator under development for schizophrenia and other neuropsychiatric disorders. Reviva has also explored development opportunities in pulmonary arterial hypertension and idiopathic pulmonary fibrosis through additional pipeline assets. The company traces its origins to research and development activities initiated by founder and scientist Dr. Laxminarayan Bhat and later became publicly traded through a business combination with a special purpose acquisition company in 2020. Reviva’s strategic positioning is tied to its differentiated CNS pipeline, orphan and specialty indications focus, and proprietary medicinal chemistry expertise.